Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Beyond CSCC, Libtayo is authorised to treat basal cell carcinoma, the most common type of skin cancer, as well as non-small cell lung cancer (NSCLC). Regeneron recently presented five-years results ...

Libtayo has been approved by regulatory authorities in more than 30 countries in one or more indications, including for certain adult patients with advanced basal cell carcinoma (BCC), advanced CSCC, ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small ...

It is looking to strengthen its oncology franchise, which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous ...

The EC approval also now means that Libtayo can be used to treat certain patients across four types of cancer within the European Union: advanced squamous cell carcinoma (SCC), advanced basal cell ...

REGN is looking to strengthen its oncology franchise, which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous ...

Libtayo is a fully human monoclonal antibody designed to target PD-1, in turn blocking the cancer cells’ immune evasion mechanism. The treatment has been so far approved for certain types of CSCC, ...

Libtayo is indicated for the treatment of patients with locally advanced basal cell carcinoma (laBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is ...